Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Closed-loop brain neurofeedback on the left prefrontal cortex to lower stress-related heart responses in people with coronary heart disease and anxiety.

Official title: Closed-Loop Neurofeedback Targeting the Left Dorsolateral Prefrontal Cortex for Cardiac Autonomic Modulation in Coronary Artery Disease With Anxiety - A Randomized, Sham-Controlled Trial (HEART-SET-2)

Run by Shenyang Medical College · NCT07244484 · Data updated 2026-11-12

This trial will test whether closed‑loop fNIRS neurofeedback aimed at the left dorsolateral prefrontal cortex can lower heart rate during a cold‑pain stress test in adults with stable coronary heart disease and anxiety.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment56 (estimated)
SponsorShenyang Medical College
Academic / other
Locations1 site (Shenyang, Liaoning)
StatusRecruiting
StartedNovember 23, 2025
Main results expectedMay 23, 2026
Study endsMay 30, 2026
Registry record updatedApril 22, 2026
Trial IDNCT07244484 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 with confirmed stable coronary heart disease, a DSM‑5 anxiety disorder, right‑handedness, resting heart rate 60–100 bpm, HAMA score ≥16 and HAMD‑17 score ≤17 who can attend site visits and tolerate fNIRS and cold‑pressor testing are ideal candidates.

Probably not a fit

Patients with unstable cardiac conditions (for example acute unstable angina, severe congestive heart failure NYHA class IV), atrial fibrillation, significant valvular disease, unstable blood pressure, or those unable to undergo fNIRS or cold‑pain testing are unlikely to receive benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This exploratory interventional trial uses real‑time fNIRS-based closed‑loop neurofeedback to train left dorsolateral prefrontal cortex (DLPFC) activation in adults with stable coronary heart disease and comorbid anxiety. Participants receive either real left DLPFC neurofeedback or a sham control while undergoing standardized cold‑induced pain stress, and baseline‑corrected heart rate during the stress window is the primary physiological outcome. The study also measures participants' ability to volitionally upregulate left DLPFC activation, interhemispheric DLPFC synchronisation, and records adverse events during training and experimental sessions. Analyses will test whether changes in heart rate are associated with and partly mediated by changes in DLPFC activation or interhemispheric synchrony.

Why it matters

Potential benefit: If successful, this approach could reduce stress‑related heart rate surges and improve cardiac autonomic regulation in people with coronary heart disease and anxiety.

How similar studies have gone: Preliminary neurofeedback work in healthy and psychiatric samples has shown some ability to change prefrontal activity and autonomic markers, but closed‑loop fNIRS neurofeedback specifically targeted to left DLPFC in coronary heart disease with anxiety is largely novel and unproven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \>18 years, any sex.
* Right-handed, with resting heart rate between 60 and 100 beats per minute.
* Confirmed diagnosis of CHD, defined as at least one of the following:

  (i) positive stress test; (ii) documented myocardial infarction (MI) with electrocardiographic changes and concurrent elevation of creatine kinase MB isoenzyme or troponin; (iii) angiographically confirmed coronary atherosclerosis with ≥50% stenosis in at least one coronary artery.
* Diagnosis of an anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
* Hamilton Anxiety Rating Scale (HAMA) score ≥16 and 17-item Hamilton Depression Rating Scale (HAMD-17) score ≤17.

Exclusion Criteria:

* Acute unstable angina.
* Severe congestive heart failure (New York Heart Association \[NYHA\] class IV).
* Valvular heart disease.
* History of atrial fibrillation.
* Unstable blood pressure, defined as systolic blood pressure \>180 mmHg or \<90 mmHg.
* Pregnancy.
* History of unstable medical conditions, including cerebrovascular disease, dementia, hyperthyroidism, pulmonary disease, or malignancy. These are assessed through medical history, electronic health records, physical examination, and ECG findings.
* High risk of suicide or homicide.
* Presence of other psychiatric disorders, including psychotic disorders, bipolar disorder, or active substance use disorders.
* Use of psychotropic medication within 1 month prior to enrolment, to avoid potential interference with haemodynamic measurements.

Where it's running

  • Second Affiliated Hospital of Shenyang Medical College
    Shenyang, Liaoning, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.